FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Regulatory Review Determined for Welireg

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Peloton Therapeutics Welireg (belzutifan).

latest-news-card-1
Medical Devices

Cardinal Health Recalls Procedure Kits

Cardinal Health recalls its Covidien and Cardinal Health brand urology and operating room-specific kits and trays that contain 0.9% sodium chloride ir...

latest-news-card-1
Human Drugs

Guide on Drug Supply Chain Security

FDA issues a guidance entitled Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs.

latest-news-card-1
Medical Devices

Getinge Recalls CardioHelp Emergency Drive

Getinge recalls its CardioHelp Emergency Drive due to a possible blocking or impairment of its emergency crank.

latest-news-card-1
Federal Register

FDA Withdraws Ciprofloxacin for Cystitis

Federal Register notice: FDA withdraws approval of Bayers Cipro (ciprofloxacin HCl) oral tablets under NDA #019537 and five related ANDAs that referen...

latest-news-card-1
Federal Register

Info Collection on OTC Drugs

Federal Register notice: FDA sends to OMB an information collection revision entitled Time and Extent Applications (TEA) for Nonprescription Drug Prod...

latest-news-card-1
Biologics

First Sickel Cell Gene Therapies Approved

The first two cell-based gene therapies for treating sickle cell disease in patients 12 years and older gain FDA approval Vertex Pharmaceuticals Casg...

latest-news-card-1
Human Drugs

Novartis Reports Risk Reduction Kisqali Data

Novartis reports updated Kisqali (ribociclib) data from the Phase 3 NATALEE trial that confirms an earlier benefit seen at an interim analysis.

latest-news-card-1
Human Drugs

Alpha Cognition NDA for Alzheimers Filed

FDA accepts for review an Alpha Cognition NDA for ALPHA-1062 for treating mild-to-moderate Alzheimers disease.

latest-news-card-1
Human Drugs

Positive Phase 1/2 Linvoseltamab Results to FDA

Regeneron says it will submit a BLA to FDA this year for its linvoseltamab multiple myeloma drug based on successful Phase 1/2 trial results.